| Field | Specification |
|---|---|
| Mfr No | |
| Clonality | |
| Host | |
| Immunogen | Raised against Vaccinia-E2 followed by intravenous injection of the maltose binding protein MBP-E2 |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target | |
| UniProt # |
Overview
The human papilloma virus (HPV) family of DNA tumor viruses includes HPV16, a strain that is responsible for the largest number of cases of cervical cancers linked to the family. HPV16E1 and HPV16E2 are proteins that are involved in the regulation of viral DNA replication and are important for infected cell homeostasis. HPV16E2 specifically regulates the expression of the E6 and E7 oncoproteins by binding to four sites within the viral long control region, possibly involving interactions with nuclear hormone receptors. Integration of the HPV genome into the host DNA usually disrupts the HPV16E2 gene open reading frames, resulting in an overexpression of E6 and E7 genes, an event that may lead to the malignant transformation of cervical cancer. HPV16E2 is also able to induce apoptotic cell death via two pathways: the first through the binding of p53 and the second through the binding of the viral genome.
This anti-HPV16 E2 antibody is supplied as Purified (Mouse, Monoclonal (mouse origin), clone TVG 261, Mouse IgG1, kappa, Unconjugated) and is designed to support common target-detection workflows after the on-page specifications.
Key elements and design rationale
- Target: HPV16 E2
- Format: Purified
- Localization: Nuclear
- Species reactivity: Type 16 of Human Papilloma Virus (HPV-16)
- Applications (listed): WB
- Conjugate: Unconjugated
- Clone and antibody class: Monoclonal (mouse origin), clone TVG 261, Mouse IgG1, kappa
Because antibody performance can depend on epitope context, sample preparation, and biological state, interpret signals using appropriate controls and orthogonal evidence when possible.
Biological background
HPV16 E2 is referenced in public gene/protein resources (e.g., UniProt and NCBI Gene), which provide curated names/synonyms, protein features, and pathway context. When designing assays, consider potential isoforms, post-translational modifications, and cell-type specific expression that may influence observed signal.
Research relevance and current trends
- Profiling HPV16 E2 expression across model systems, perturbations, and time points to support mechanistic hypotheses.
- Combining antibody-based detection with multi-omics or imaging readouts to link HPV16 E2 signal with phenotype.
- Using well-matched controls (isotype controls, genetic perturbations, or independent reagents) to strengthen interpretation of target-associated signal.
Common research applications
- WB
Use the listed applications as a starting point and tailor experimental design to your sample type and readout requirements.
Notes for experimental interpretation
- Specificity considerations: closely related family members, isoforms, or PTMs can affect apparent specificity; confirm with independent approaches when critical.
- Controls: include negative controls and, when feasible, genetic or pharmacologic perturbations to support target attribution in your system.
- Species and sample context: differences in sequence, expression, fixation, or extraction conditions can change signal behavior across models.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.